 | |||
|
ECOG Introduction to ECOG Clinical Trials Guide For Cancer Patients What is a clinical trial? Why participate? Does insurance cover costs? What if I change my mind? How can I join a clinical trial? ECOG's active protocols Educational Materials Selenium E5597 GI Studies E4203,E5202,E5204 Head & Neck Cancer E1305 *NEW* Lung Cancer E1505 *NEW* Lung Cancer E1508 *NEW* Lung Cancer E4508 *NEW* Melanoma E2603 Prostate CHAARTED E3805 Cancer in Siblings E1Y97 Non-Hodgkins Lymphoma E4402 Breast Cancer PACCT1: TAILORx Informational Videos Trial Summary Results Trial Monitoring ECOG Data Monitoring Committee ECOG Institutions Institutions by state Alphabetical listing Joining ECOG Joining ECOG Publications Publications bibliography Announcements TAILORx Webinar Information NCI Press Release: Bevacizumab... Job Openings Future ECOG Meeting Dates Researcher Advocate Partners Young Investigator Symposium NCI-VA Initiative Scales and Criteria ECOG Performance Status Common Toxicity Criteria Cancer Information Colon Cancer Video Cancer Survivor Publications Releasing Results Guidelines Other Cancer Sites ECOG Main Institutions' Sites Other Cooperative Groups Advocates/Support Groups 
ECOG MEMBERS
|
NCI Press Release: Bevacizumab Combined With Oxaliplatin-Based Chemotherapy Prolongs Survival for Previously Treated Patients With Advanced Colorectal CancerRecently, the NCI released preliminary results from the ECOG-led E3200 Phase III Trial of Bevacizumab, Oxaliplatin, 5-FU, and Leucovorin vs. Oxaliplatin, 5-FU and Leucovorin vs. Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer. These findings yield a major significance on the scientific community and the patient population. With this information, we can expect survival for people with advanced colorectal cancer to be more than double what it was just a few years ago. Click on the following link to read the full release.
Return to ECOG Home Page
All contents copyright © 1999-2001 Eastern Cooperative Oncology Group.
|